论文部分内容阅读
目的研究卡培他滨(EXC)联合奥沙利铂(OXA)术前新辅助化疗治疗中晚期胃癌的临床效果。方法选择2009年1月至2011年12月治疗的86例中晚期胃癌患者。以数字法随机分为观察组(43例)和对照组(43例),对照组予以顺铂和氟尿嘧啶联合化疗,观察组予以EXC和OXA术前新辅助化疗。对比两组的疗效、肿瘤复发率、生存率及不良反应情况。结果两组的疗效差异无统计学意义(P>0.05)。观察组的复发率低于对照组,1、2年生存率高于对照组,差异均有统计学意义(均P<0.05)。两组不良反应方面差异无统计学意义(P>0.05)。结论 EXC与OXA联合中晚期胃癌患者术的前新辅助化疗有良好的临床疗效,复发率和不良反应较低,中期生存率较高,安全可靠,值得临床推广。
Objective To study the clinical efficacy of capecitabine (EXC) combined with oxaliplatin (OXA) preoperative neoadjuvant chemotherapy in the treatment of advanced gastric cancer. Methods 86 patients with advanced gastric cancer who were treated from January 2009 to December 2011 were selected. The patients in the observation group were randomly divided into observation group (43 cases) and control group (43 cases). The control group was given cisplatin and fluorouracil combined with chemotherapy. The observation group was given neoadjuvant chemotherapy with EXC and OXA. The curative effect, tumor recurrence rate, survival rate and adverse reactions of the two groups were compared. Results There was no significant difference in curative effect between the two groups (P> 0.05). The recurrence rate of the observation group was lower than that of the control group, and the 1-year and 2-year survival rates were significantly higher than those of the control group (all P <0.05). Adverse reactions between the two groups showed no significant difference (P> 0.05). Conclusion Preoperative neoadjuvant chemotherapy combined with EXX and OXA in patients with advanced gastric cancer has good clinical efficacy, low recurrence rate and adverse reactions, high mid-term survival rate, safe and reliable, and worthy of clinical promotion.